+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Short Bowel Syndrome Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896353
  • Report
  • January 2020
  • Region: Global
  • 110 pages
  • Mordor Intelligence
UP TO OFF
until Mar 31st 2020
1 of 4

FEATURED COMPANIES

  • Ardelyx Inc
  • GlyPharma Therapeutics
  • Merck KGaA
  • Naia Pharmaceuticals Inc
  • Nutrinia Inc
  • OxThera Inc
  • MORE
Market Overview

The Short Bowel Syndrome (SBS) Market studied was anticipated to grow with a CAGR of nearly 29.8%, during the forecast period. The major factors attributing to the growth of the SBS market are rise in global prevalence of GI disorders like volvulus, Inflammatory bowel disease (IBD), in particular, Crohn’s disease (CD), which predisposes patients to development of SBS and mesenteric ischemia, which are the most common causes for SBS among all the age groups which demand the necessity of the treatment. For instance, in 2015, according to CDC, about 3 million adults of the United States were diagnosed with IBD which is a major cause of SBS. Additionally, the increased awareness programs led by several associations like the Association of gastrointestinal motility, Oley Foundation and the SBS Cure Project coupled with rising in the government health care expenditure are likely to drive the market growth over the forecast period.

Scope of the Report

Short bowel syndrome (SBS) is a metabolic disorder that occurs due to the malfunctioning or removal of the small intestine through surgery due to digestive illness. The consequences may be malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition. Short bowel syndrome is detected in Crohn’s disease, radiation enteritis, and mesenteric ischemia. If left untreated, SBS can lead to complications such as anemia and kidney stones.

Key Market Trends

GLP-2 Drug Therapy by Drug Class is Expected to Hold the Largest Market Share in the Short Bowel Syndrome Market
  • The GLP-2 drug treatment accounts for the major market share throughout the forecast period. The dominance is due to the only products available for treatment with the brand names Gattex and Revestive, introduced by Takeda which were approved for sales in both the US and Europe respectively.
  • Also, the patent exclusivity of GLP-2 drug is anticipated to contribute to its significant share in the revenue of the global short bowel syndrome market.
  • By distribution channels, hospital pharmacies are accounted for the highest market share due to the rapid implementation of therapy due to a huge patient pool. Also, the preference by the patients due to unaffordability and higher expensive parenteral nutrition along with prescription products contribute to a major share in the global short bowel syndrome market.
North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall SBS market, throughout the forecast period. This dominance is mainly due to the revenue generated by the Gattex, the only glucagon-like peptide-2 (GLP-2) analog approved that improves intestinal absorption in patients with SBS in the U.S. Also, rise in the sedentary lifestyle that led no time to focus on nutritious and healthy food with increased consumption of unhealthy and junk food, resultant intestinal disorders are a major factor that drives the market growth in the region.

Europe is the second most prominent region in the global SBS market, which is due to research grants by the public & private players in the European countries to fuel the R&D of SBS drugs. Also, rapid approval of drugs like Revestive to treat SBS by the European Medical Agency is expected to drive the market growth in the region and propel the global market revenue.

The Asia Pacific is anticipated to grow at the fastest rate during the forecast period. It is due to the huge patient pool in China and India, and the uncontrolled consumption of antibiotics in India. Also, the research activities and investments on R&D in the region are estimated to fuel the growth of the SBS market in the Asia Pacific and attribute to a significant share in the global market.

Competitive Landscape

The global short bowel syndrome market is moderately competitive and consists of several prominent industry players. Some prominent players are making partnerships and acquiring the blockbuster products in the market, other companies and expanding their market position globally. For instance, Takeda acquired the Shire, to expanding its geographic footprint and to be a leader in providing targeted treatments in gastroenterology, the leading companies in gastroenterology (GI) and neuroscience. While other key players are focusing on distributing and manufacturing of over-the-counter dietary supplements. Whereas, some companies such as Naia Pharmaceuticals SBS, Micelle BioPharma, Inc. are having new products in their pipeline. Some of the companies which are currently dominating the market are TAKEDA Inc, Naia Pharmaceuticals Inc, VectivBio AG, OxThera Inc, and Nutrinia Inc.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Ardelyx Inc
  • GlyPharma Therapeutics
  • Merck KGaA
  • Naia Pharmaceuticals Inc
  • Nutrinia Inc
  • OxThera Inc
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Prevalence of Short Bowel Syndrome and Awareness Programs by Non-Profit Organizations
4.2.2 Highly Expensive and Uncomfortable Parenteral Nutrition
4.3 Market Restraints
4.3.1 Lack of Availability of the Approved Drugs in Developing Countries
4.3.2 Lethal Adverse Complications like Colonic Cancer, Polyps along with Common Side Effects Associated with the Medication
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 Drug Class
5.1.1 GLP-2
5.1.2 Growth Hormone
5.1.3 Glutamine
5.1.4 Others
5.2 Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 TAKEDA Inc
6.1.2 Naia Pharmaceuticals Inc
6.1.3 OxThera Inc
6.1.4 VectivBio AG
6.1.5 Nutrinia Inc
6.1.6 Merck KGaA
6.1.7 GlyPharma Therapeutics
6.1.8 Sancilio & Company
6.1.9 Ardelyx Inc
6.1.10 Zealand Pharma

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • TAKEDA Inc
  • Naia Pharmaceuticals Inc
  • OxThera Inc
  • VectivBio AG
  • Nutrinia Inc
  • Merck KGaA
  • GlyPharma Therapeutics
  • Sancilio & Company
  • Ardelyx Inc
  • Zealand Pharma
Note: Product cover images may vary from those shown
Adroll
adroll